COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01946204
Recruitment Status : Active, not recruiting
First Posted : September 19, 2013
Results First Posted : June 19, 2018
Last Update Posted : May 7, 2019
Information provided by (Responsible Party):
Aragon Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: Apalutamide Drug: Placebo Phase 3

Detailed Description:

This Phase 3 clinical trial is an essential step in the evaluation of an investigational medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN study is to compare the safety and effectiveness of the investigational medication to placebo in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill that looks like the investigational medication but does not contain any active medication, a dummy pill.

Phase 3 studies are performed after preliminary evidence suggesting effectiveness of the drug has been obtained in previous Phase 2 studies. These studies are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug.

Study participants will take the oral investigational medication daily. One cycle of study treatment lasts 4 weeks or 28 days. The number of cycles will depend on how you and your cancer respond to the study medication.

In order for the researchers to evaluate and compare the study results, there are two different study groups. Study participants will be randomly (like flipping a coin) assigned to one of these groups:

  • One group will receive their current treatment along with the investigational medication
  • One group will receive their current medications along with a placebo

The investigational medication will be given to 2 out of every 3 study participants. Neither you nor the study staff will know which group you are in. However, in case of a medical emergency, your study doctor can quickly find out which treatment group you are in.

All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and you may remain on investigational treatment until your disease worsens, or until significant side effects occur or you can no longer tolerate treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1207 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Actual Study Start Date : October 14, 2013
Actual Primary Completion Date : May 19, 2017
Estimated Study Completion Date : November 29, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Apalutamide

Arm Intervention/treatment
Experimental: Treatment Arm A: Apalutamide Drug: Apalutamide
240 mg tablets administered by mouth on a continuous once daily dosing regimen

Placebo Comparator: Treatment Arm B: Placebo Drug: Placebo
Matched placebo tablets administered by mouth on a continuous once daily dosing regimen

Primary Outcome Measures :
  1. Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 43 Months ]
    MFS was defined as the time from randomization to the time of first evidence of BICR-confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. The MFS data for participants without metastasis or death were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and computerized tomography [CT] or magnetic resonance imaging [MRI] of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.

Secondary Outcome Measures :
  1. Time to Metastasis (TTM) [ Time Frame: Up to approximately 43 Months ]
    Time to metastasis (TTM) was defined as the time from randomization to the time of the scan that showed first evidence of BICR-confirmed radiographically detected bone or soft tissue distant metastasis. The TTM data for participants without metastasis were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and CT or MRI of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.

  2. Progression-free Survival (PFS) [ Time Frame: Up to approximately 43 Months ]
    PFS defined as time from randomization to first documentation of BICR-confirmed radiographic progressive disease (PD) (development of distant/local/regional metastasis)/death due to any cause whichever occurred first. PFS data for participants without loco-regional disease were performed for US/ex-US regulatory purposes. Radiographic scans (bone scans and CT/MRI of chest,abdomen,pelvis) performed for detection of metastasis throughout study. PD based on RECIST v1.1; Subjects with one measurable lesion, At least 20% increase in sum of diameters of target lesions taking as reference smallest sum on study. In addition, sum must demonstrate an absolute increase of at least 5 millimeter(mm). Also, appearance of one/more new lesions was also considered PD. Subjects with non-measurable disease as per CT/MRI scans, unequivocal progression/appearance of one or more new lesions was considered PD. For new bone lesions detected on bone scans, second imaging (CT/MRI) was required to confirm PD.

  3. Time to Symptomatic Progression [ Time Frame: Up to approximately 43 Months ]
    Time to symptomatic progression was defined as the time from randomization to documentation in the CRF of any of the following (whichever occurred earlier): a) development of a skeletal-related event (pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone); b) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy; or c) development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.

  4. Overall Survival [ Time Frame: Up to approximately 43 months ]
    Overall survival was defined as the time from randomization to the date of death due to any cause.

  5. Time to Initiation of Cytotoxic Chemotherapy [ Time Frame: Up to approximately 43 months ]
    Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or equal to (<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)
  • Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3 PSA rises, at least 1 week apart, with the last PSA greater than (>) 2 nanogram per milliliter (ng/mL)
  • Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study
  • Patients currently receiving bone loss prevention treatment with bone-sparing agents must be on stable doses for at least 4 weeks prior to randomization
  • Patients who received a first generation anti-androgen (for example, bicalutamide, flutamide, nilutamide) must have at least a 4-week washout prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) after washout
  • At least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization
  • At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization
  • Eastern Cooperative Oncology Group Performance Status 0 or 1
  • Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade <= 1 or baseline prior to randomization
  • Adequate organ function according to protocol-defined criteria
  • Administration of growth factors or blood transfusions will not be allowed within 4 weeks of the hematology labs required to confirm eligibility

Exclusion Criteria:

  • Presence of confirmed distant metastases, including central nervous system and vertebral or meningeal involvement
  • Symptomatic local or regional disease requiring medical intervention
  • Prior treatment with second generation anti-androgens
  • Prior treatment with CYP17 inhibitors
  • Prior treatment with radiopharmaceutical agents, or any other investigational agent for non-metastatic castration-resistant prostate cancer
  • Prior chemotherapy for prostate cancer except if administered in the adjuvant/neoadjuvant setting
  • History of seizure or condition that may pre-dispose to seizure
  • Concurrent therapy with protocol-defined excluded medications
  • History or evidence of any of the following conditions: any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization; severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or clinically significant ventricular arrhythmias within 6 months prior to randomization; uncontrolled hypertension; gastrointestinal disorder affecting absorption; active infection; and, any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01946204

Hide Hide 391 study locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, Alaska
Anchorage, Alaska, United States
United States, Arizona
Chandler, Arizona, United States
Tucson, Arizona, United States
United States, California
Duarte, California, United States
Fullerton, California, United States
Laguna Woods, California, United States
Los Angeles, California, United States
Orange, California, United States
Roseville, California, United States
Sacramento, California, United States
San Bernardino, California, United States
San Diego, California, United States
San Francisco, California, United States
Santa Monica, California, United States
Sherman Oaks, California, United States
Stanford, California, United States
Tarzana, California, United States
Torrance, California, United States
United States, Colorado
Denver, Colorado, United States
Englewood, Colorado, United States
Glenwood Springs, Colorado, United States
Grand Junction, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Aventura, Florida, United States
Boca Raton, Florida, United States
Bradenton, Florida, United States
Daytona Beach, Florida, United States
Fort Myers, Florida, United States
Hialeah, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
New Port Richey, Florida, United States
Orlando, Florida, United States
Saint Petersburg, Florida, United States
Sarasota, Florida, United States
Wellington, Florida, United States
United States, Idaho
Meridian, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
Decatur, Illinois, United States
Maywood, Illinois, United States
Melrose Park, Illinois, United States
United States, Indiana
Carmel, Indiana, United States
Jeffersonville, Indiana, United States
Muncie, Indiana, United States
United States, Iowa
West Des Moines, Iowa, United States
United States, Kansas
Westwood, Kansas, United States
Wichita, Kansas, United States
United States, Louisiana
Metairie, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Annapolis, Maryland, United States
Baltimore, Maryland, United States
Rockville, Maryland, United States
Towson, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
Lansing, Michigan, United States
Minneapolis, Michigan, United States
Royal Oak, Michigan, United States
United States, Minnesota
Duluth, Minnesota, United States
United States, Mississippi
Bay Saint Louis, Mississippi, United States
Southaven, Mississippi, United States
United States, Missouri
Kansas City, Missouri, United States
United States, Montana
Missoula, Montana, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Hampshire
Hooksett, New Hampshire, United States
United States, New Jersey
Hackensack, New Jersey, United States
Lawrenceville, New Jersey, United States
Morristown, New Jersey, United States
Mount Laurel, New Jersey, United States
New Brunswick, New Jersey, United States
Voorhees, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Albany, New York, United States
Bronx, New York, United States
Mineola, New York, United States
New York, New York, United States
Oneida, New York, United States
Poughkeepsie, New York, United States
Syracuse, New York, United States
United States, North Carolina
Concord, North Carolina, United States
Greensboro, North Carolina, United States
Greenville, North Carolina, United States
Salisbury, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Middleburg Heights, Ohio, United States
Middletown, Ohio, United States
United States, Oregon
Bend, Oregon, United States
Portland, Oregon, United States
Tualatin, Oregon, United States
United States, Pennsylvania
Bala-Cynwyd, Pennsylvania, United States
Bryn Mawr, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Warwick, Rhode Island, United States
United States, South Carolina
Charleston, South Carolina, United States
Greenville, South Carolina, United States
Myrtle Beach, South Carolina, United States
West Columbia, South Carolina, United States
United States, Tennessee
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Abilene, Texas, United States
Amarillo, Texas, United States
Dallas, Texas, United States
Fort Sam Houston, Texas, United States
Houston, Texas, United States
McAllen, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Norfolk, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Burien, Washington, United States
Edmonds, Washington, United States
Seattle, Washington, United States
Tacoma, Washington, United States
United States, Wisconsin
Green Bay, Wisconsin, United States
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Adelaide, Australia
Box Hill, Australia
Camperdown, Australia
Darlinghurst, Australia
Geelong, Australia
Gosford, Australia
Hobart, Australia
Kogarah, Australia
Liverpool, Australia
Melbourne, Australia
Nedlands, Australia
Parkville, Australia
South Woodville, Australia
Southport, Australia
Sydney, Australia
Tweed Heads, Australia
Wollongong, Australia
Graz, Austria
Innsbruck, Austria
Linz, Austria
Wien, Austria
Brussels, Belgium
Brussel, Belgium
Gent, Belgium
Kortrijk, Belgium
Leuven, Belgium
Liege, Belgium
Ottignies, Belgium
Canada, Alberta
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Canada, British Columbia
Abbotsford, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Canada, New Brunswick
Moncton, New Brunswick, Canada
Saint John, New Brunswick, Canada
Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Canada, Ontario
Barrie, Ontario, Canada
Brampton, Ontario, Canada
Brantford, Ontario, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
North York, Ontario, Canada
Oakville, Ontario, Canada
Ottawa, Ontario, Canada
Owen Sound, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Gatineau, Quebec, Canada
Granby, Quebec, Canada
Greenfield Park, Quebec, Canada
Laval, Quebec, Canada
Montreal, Quebec, Canada
Pointe-Claire, Quebec, Canada
Sherbrooke, Quebec, Canada
Kelowna, Canada
Montrel, Canada
Quebec, Canada
Toronto, Canada
Liberec, Czechia
Olomouc, Czechia
Opava, Czechia
Plzen, Czechia
Praha 2, Czechia
Praha 4, Czechia
Praha 5, Czechia
Praha, Czechia
Aalborg C, Denmark
Copenhagen, Denmark
Odense N/a, Denmark
Roskilde, Denmark
Helsinki, Finland
Oulu, Finland
Seinäjoki, Finland
Tampere, Finland
Turku, Finland
Angers Cedex 9, France
Angers, France
Besancon, France
Bordeaux, France
Caen Cédex 05, France
Clermont Ferrand, France
Hyers, France
La Roche sur Yon Cedex 9, France
Le Mans, France
Lille Cedex N/a, France
Lyon, France
Marseille cedex 5, France
Marseille Cedex 9, France
Nice Cedex 2, France
Nîmes Cedex 9, France
Paris 75, France
Paris Cedex 15, France
Paris, France
Reims Cedex, France
Rennes Cedex, France
Rouen, France
Saint Gregoire, France
Saint Herblain, France
Strasbourg, France
Suresnes, France
Tours, Cedex 9, France
Vandoeuvre Les Nancy Cedex, France
Aachen, Germany
Bergisch Gladbach, Germany
Berlin, Germany
Braunschweig, Germany
Duisburg, Germany
Emmendingen, Germany
Frankfurt / Main, Germany
Greifswald, Germany
Göttingen, Germany
Hamburg, Germany
Hannover, Germany
Heidelberg, Germany
Heinsberg, Germany
Homburg/Saar, Germany
Jena, Germany
Kiel, Germany
Kirchheim unter Teck, Germany
Köln, Germany
Magdeburg, Germany
Mainz, Germany
Mannheim, Germany
Marburg, Germany
Mettmann, Germany
Müllheim, Germany
Münster, Germany
Nuertingen, Germany
Regensburg, Germany
Rostock, Germany
Tübingen, Germany
Weiden, Germany
Wilhelmshaven, Germany
Wuppertan, Germany
Zirndorf, Germany
Budapest, Hungary
Miskolc, Hungary
Nyíregyhá, Hungary
Sopron, Hungary
Szentes, Hungary
Haifa, Israel
Jeruselem, Israel
Kfar-Saba, Israel
Petah-Tikva, Israel
Ramat Gan, Israel
Tel Aviv, Israel
Zerifin, Israel
Akita, Japan
Fukuoka-shi, Japan
Gifu, Japan
Hakodate, Japan
Hiroshima, Japan
Hokkaido, Japan
Kanazawa, Japan
Kashiwa, Japan
Kita-Gun, Japan
Kobe, Japan
Koshigaya, Japan
Kumamoto, Japan
Kurume, Japan
Matsuyama, Japan
Nagano, Japan
Nagasaki, Japan
Nagoya, Japan
Niigata, Japan
Osaka-Sayama, Japan
Osaka, Japan
Sagamihara, Japan
Sakura, Japan
Sapporo, Japan
Shinjuku-Ku, Japan
Tokushima, Japan
Tokyo, Japan
Ube, Japan
Wakayama, Japan
Yokohama, Japan
Korea, Republic of
Daegu, Korea, Republic of
Gwangju-si, Korea, Republic of
Pusan, Korea, Republic of
Seongnam, Korea, Republic of
Seoul, Korea, Republic of
Alkmaar, Netherlands
Eindhoven, Netherlands
Hoofddorp, Netherlands
Leidschendam, Netherlands
Nijmegen, Netherlands
Rotterdam, Netherlands
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Hamilton, New Zealand
Nelson City, New Zealand
Tauranga, New Zealand
Whangarei, New Zealand
Nordbyhagen, Norway
Bialystok, Poland
Bydgoszcz, Poland
Gdansk, Poland
Kutno, Poland
Lodz, Poland
Poznan, Poland
Szczecin, Poland
Torun, Poland
Warszawa, Poland
Wroclaw, Poland
Baia Mare, Romania
Brasov, Romania
Bucharest, Romania
Cluj- Napoca, Romania
Targu Mures, Romania
Russian Federation
Barnaul, Russian Federation
Ekaterinburg, Russian Federation
Ivanovo, Russian Federation
Moscow, Russian Federation
Obninsk, Kaluga Region, Russian Federation
Omsk, Russian Federation
Ryazan, Russian Federation
Saint Petersburg, Russian Federation
St. Petersburg, Russian Federation
Ufa, Russian Federation
Yaroslavl, Russian Federation
Banska Bystrica, Slovakia
Bratislava, Slovakia
Martin, Slovakia
Nitra, Slovakia
Trenčín, Slovakia
Badalona, Spain
Barcelona, Spain
Castellon, Spain
Coruña, Spain
Girona, Spain
Guadalajara, Spain
Jerez de la Frontera, Spain
Las Palmas De Gran Canaria, Spain
Madrid, Spain
Murcia, Spain
Málaga, Spain
Palma de Mallorca, Spain
Pamplona, Spain
Sabadell, Spain
Salamanca, Spain
San Sebastian de los Reyes, Spain
Santander, Spain
Sevilla N/a, Spain
Sevilla, Spain
Valencia, Spain
Goteborg, Sweden
Stockholm, Sweden
Umea, Sweden
Uppsala, Sweden
Örebro, Sweden
Kaohsiung, Taiwan
Taichung, Taiwan
Taipei, Taiwan
Taoyuan County, Taiwan
United Kingdom
Blackburn, United Kingdom
Cambridge, United Kingdom
Cardiff, United Kingdom
Dundee, United Kingdom
Glasgow, United Kingdom
Guildford, United Kingdom
Leeds, United Kingdom
London, United Kingdom
Maidstone, United Kingdom
Nottingham, United Kingdom
Plymouth, United Kingdom
Southampton, United Kingdom
Surrey, United Kingdom
Swansea, United Kingdom
Wirral, United Kingdom
Wolverhampton, United Kingdom
Sponsors and Collaborators
Aragon Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Aragon Pharmaceuticals, Inc. Clinical Trial Aragon Pharmaceuticals, Inc.
  Study Documents (Full-Text)

Documents provided by Aragon Pharmaceuticals, Inc.:
Study Protocol  [PDF] March 15, 2017
Statistical Analysis Plan  [PDF] June 26, 2017

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aragon Pharmaceuticals, Inc. Identifier: NCT01946204    
Other Study ID Numbers: CR102931
ARN-509-003 ( Other Identifier: Aragon Pharmaceuticals, Inc. )
2012-004322-24 ( EudraCT Number )
First Posted: September 19, 2013    Key Record Dates
Results First Posted: June 19, 2018
Last Update Posted: May 7, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aragon Pharmaceuticals, Inc.:
Prostate neoplasms
Prostate cancer
Castration-resistant prostate cancer
Non-metastatic castration-resistant prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases